随着减重药巨头诺和诺德重磅GLP-1类药物司美格鲁肽在中国的核心分子专利即将于3月到期，一大批中国本土的司美格鲁肽仿制药正在获批路上。据公开信息，目前国内市场上包括九源基因、丽珠集团、华东医药、齐鲁制药、正大天晴在内的十多家本土制药公司的司美格鲁肽仿制药有望在不久的将来上市，还有十余款处于三期临床，一场价格大战即将席卷。一位内分泌专家表示，随着更多仿制药的上市，减重药很快就会迎来“白菜价”时代。（第一财经）
This started with Addition Under Pressure, where I gave Claude Code and Codex the same prompt: train the smallest possible transformer that can do 10-digit addition with at least 99% accuracy. Claude Code came back with 6,080 parameters and Codex came back with 1,644. The community has since pushed this dramatically lower.
，这一点在heLLoword翻译官方下载中也有详细论述
如果说亚光科技呈现的是制造端与资本扩张错位的代价，那么另一条更激进的路径——高溢价跨境并购，风险更为直接。
It's worth noting that these benchmarks compare a pure TypeScript/JavaScript implementation of the new API against the native (JavaScript/C++/Rust) implementations of Web streams in each runtime. The new API's reference implementation has had no performance optimization work; the gains come entirely from the design. A native implementation would likely show further improvement.